Pharmacology Exam 1 Flashcards

1
Q

Chemical name

A

A drug name that is derived from the specific chemical structure of the compound. Chemical names are not used clinically but are shortened in some way to form the drug’s generic name.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Controlled substances

A

Drugs designated by the federal government as having increased potential for abuse and illegal use. These substances are grouped into five categories (schedules), with schedule I substances having the highest abuse potential and schedule V substances having a relatively low potential for abuse.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Dose-response curve

A

The relationship between incremental doses of a drug and the magnitude of the reaction that those doses will cause.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Generic name

A

The name applied to a drug, which is not protected by a trademark; usually a shortened version of the drug’s chemical name (SYN: nonproprietary name).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Median effective dose (ED50)

A

The drug dose that produces a specific therapeutic response in 50 percent of the patients in whom it is tested.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Median lethal dose (LD50)

A

The drug dose that causes death in 50 percent of the experimental animals in which it is tested.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Median toxic dose (TD50)

A

The drug dose that produces a specific adverse (toxic) response in 50 percent of the patients in whom it is tested.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Nonproprietary name

A

A drug name that is usually a shortened version of the drug’s chemical name and is recognized as the standard name for that drug regardless of the drug’s trade or brand names (SYN: generic name).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Off-label prescribing

A

A drug is prescribed to treat conditions other than those approved by the FDA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Orphan drugs

A

Drugs that are designed and approved to treat rare diseases. Because these drugs are only used in a small patient population (usually less than 200,000 people), financial and other incentives are often provided by various sources to encourage a drug company to develop and market the drug.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Over-the-counter drugs (OTC)

A

Drugs that can be purchased directly by the consumer without a prescription (SYN: nonprescription drugs).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Pharmacodynamics

A

The study of how drugs affect the body—that is, the physiological and biochemical mechanisms of drug action.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pharmacogenetics

A

The study of the how genetic variability can influence drug responses and metabolism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pharmacokinetics

A

The study of how the body handles drugs—that is, the manner in which drugs are absorbed, distributed, metabolized, and excreted.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pharmacotherapeutics

A

The study of how drugs are used in the prevention and treatment of disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Pharmacy

A

The professional discipline dealing with the preparation and dispensing of medications.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Potency

A

The dose of a drug that produces a given response in a specific amplitude. When two drugs are compared, the more potent drug will produce a given response at a lower dose.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Therapeutic index (TI)

A

A ratio used to represent the relative safety of a particular drug; the larger the therapeutic index, the safer the drug. It is calculated as the median toxic dose divided by the median effective dose. (In animal trials, the median lethal dose is often substituted for the median toxic dose.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Toxicology

A

The study of the harmful effects of drugs and other chemicals.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Trade name

A

The name given to a drug by the pharmaceutical company; it is protected by a trademark and used by the company for marketing the drug (SYN: brand name or proprietary name).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Bioavailability

A

The extent to which a drug reaches the systemic circulation following administration by various routes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Buccal

A

Referring to the cheek. Drugs administered buccally are placed between the cheek and gum and are absorbed into the circulation from the mucosa lining the gums and inner cheek.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Enteral administration

A

Administration of drugs by way of the alimentary canal.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

First-pass effect

A

The phenomenon in which drugs absorbed from the stomach and small intestine must pass through the liver before reaching the systemic circulation. Certain drugs undergo extensive hepatic metabolism because of this first pass through the liver.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Intrathecal

A

Administration of substances within a sheath; typically refers to injection into the sub-arachnoid space surrounding the spinal cord.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Parenteral administration

A

Administration of drugs by routes other than via the alimentary canal: by injection, transdermally, topically, and so on.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Proton pump

A

An enzyme that moves hydrogen ions (protons) across the cell membrane. The gastric proton pump transports hydrogen ions into the stomach; drugs that inhibit this enzyme are known as proton pump inhibitors, and these drugs are used to reduce the formation and effects of excess gastric acid.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Sublingual

A

Under the tongue; drugs administered sublingually are absorbed into the systemic circulation via the venous drainage from underneath the tongue.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Volume of distribution (Vd)

A

A ratio used to estimate the distribution of a drug within the body relative to the total amount of fluid in the body. It is calculated as the amount of drug administered divided by the plasma concentration of the drug.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Biotransformation

A

Biochemical changes that occur to the drug within the body, usually resulting in the breakdown and inactivation of the drug (SYN: drug metabolism).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Clearance

A

The process by which the active form of the drug is removed from the bloodstream by either metabolism or excretion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Drug microsomal metabolizing system (DMMS)

A

A series of enzymes located on the smooth endo-plasmic reticulum that are important in catalyzing drug biotransformation.

33
Q

Half-life

A

The time required to eliminate 50 percent of the drug existing in the body.

34
Q

Metabolite

A

The compound that is formed when the drug undergoes biotransformation and is chemically altered by some metabolic process.

35
Q

Adenylate cyclase

A

An enzyme located on the inner surface of many cell membranes; it is important in mediating biochemical changes in the cell in response to drug and hormone stimulation (SYN: adenyl cyclase).

36
Q

Affinity

A

The mutual attraction between a drug and a specific cellular receptor.

37
Q

Agonist

A

A drug that binds to a receptor and causes some change in cell function (ANT: antagonist).

38
Q

Allosteric modulators

A

Substances that bind to a cell receptor and alter the receptor’s affinity for specific drugs; common allosteric modulators include guanine nucleotides, ammonium ions, calcium, and other divalent cations.

39
Q

Antagonist

A

A drug that binds to a receptor but does not cause a change in cell activity (SYN: blocker).

40
Q

Cyclic adenosine monophosphate (cAMP)

A

The ring-shaped conformation of adenosine monophosphate, which is important in acting as a second messenger in mediating the intracellular response to drug stimulation.

41
Q

Desensitization

A

A brief and transient decrease in the responsiveness of cellular receptors to drug effects.

42
Q

Down-regulation

A

A prolonged decrease in the number and/or sensitivity of drug receptors, usually occur-ring as a compensatory response to overstimulation of the receptor.

43
Q

Gamma-aminobutyric acid (GABA)

A

An inhibitory neurotransmitter in the brain and spinal cord.

44
Q

G proteins

A

Proteins that bind with guanine nucleotides and regulate cell activity. G proteins often serve as a link between surface receptors and ion channels or intracellular enzymes such as adenylate cyclase.

45
Q

Second messenger

A

The term applied to com-pounds formed within the cell, such as cyclic AMP. The second messenger initiates a series of biochemical changes within the cell following stimulation of a receptor on the cell’s outer surface by drugs, hormones, and so on.

46
Q

Selective estrogen receptor modulator (SERM)

A

A drug that activates estrogen receptors on bone and vascular tissues, while blocking estrogen receptors on breast and uterine tissues. These drugs can be used to enhance bone mineralization and to prevent certain cancers.

47
Q

Acetylcholine

A

A neurotransmitter in the somatic and autonomic nervous systems; principal synapses using acetylcholine include the skeletal neuromuscular junction, autonomic ganglia, and certain pathways in the brain.

48
Q

Adrenergic

A

Refers to synapses or physiological responses involving epinephrine and norepinephrine.

49
Q

Beta-receptor

A

A primary class of the receptors that are responsive to epinephrine and (to a lesser extent) norepinephrine. Beta receptors are subclassified into beta-1 and beta-2 receptors based on their sensitivity to various drugs.

50
Q

Cholinergic

A

Refers to synapses or physiological responses involving acetylcholine.

51
Q

Norepinephrine

A

A neurotransmitter that is import-ant in certain brain pathways and in the terminal synapses of the sympathetic nervous system (SYN: noradrenaline).

52
Q

Sympathetic

A

The sympathetic nervous system is one of the two main divisions of the autonomic nervous system

53
Q

Parasympathetic

A

The parasympathetic nervous system is one of the two main divisions of the autonomic nervous system

54
Q

Alpha-Receptor

A

A primary class of the receptors that are responsive to epinephrine and (to a lesser extent) norepinephrine. Alpha receptors are subclassified into alpha-1 and alpha-2 receptors based on their sensitivity to various drugs.

55
Q

Anticholinergics

A

Drugs that decrease activity at acetylcholine synapses. These agents are often used to diminish activity in the parasympathetic nervous system (SYN: parasympatholytic).

56
Q

Cholinergic

A

Refers to synapses or physiological responses involving acetylcholine.

57
Q

Parkinson disease or Parkinsonism

A

The clinical syndrome of bradykinesia, rigidity, resting tremor, and postural instability associated with neurotransmitter abnormalities within the basal ganglia.

58
Q

Adrenergic

A

Refers to synapses or physiological responses involving epinephrine and norepinephrine.

59
Q

Aldosterone

A

A steroid (mineralocorticoid) hormone produced by the adrenal cortex that acts on the kidney to increase sodium reabsorption, thereby retaining sodium in the body.

60
Q

Angiogenesis

A

The development of new blood vessels. Drugs that inhibit this effect can be useful in limiting the growth and proliferation of certain tumors.

61
Q

Hyperlipidemia

A

Involves abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. It is the most common form of dyslipidemia (which includes any abnormal lipid levels).

62
Q

Hypertension

A

A pathological condition characterized by a sustained, reproducible increase in blood pressure.

63
Q

Metabolic syndrome

A

A condition characterized by insulin resistance, high blood pressure, abdominal obesity, and hyperlipidemia (SYN: Syndrome X).

64
Q

Orthostatic hypotension

A

A sudden fall in blood pressure that occurs when the patient stands erect; this is a frequent side effect of many medications.

65
Q

Sympatholytics

A

Drugs that inhibit or antagonize function within the sympathetic nervous system.

66
Q

Angina pectoris

A

Severe pain and constriction in the chest region, usually associated with myocardial ischemia.

67
Q

Anticoagulation

A

A decrease in the blood’s capacity to coagulate (clot). Drugs with the ability to decrease coagulation are known as anticoagulants.

68
Q

Arrhythmia

A

A significant deviation from normal cardiac rhythm that results in a heart rate that is slower or faster than normal, or irregular (SYN: dysrhythmia).

69
Q

Congestive heart failure

A

A clinical syndrome of cardiac disease that is marked by decreased myocardial contractility, peripheral edema, shortness of breath, and decreased tolerance for physical exertion.

70
Q

Dopamine

A

A neurotransmitter located in the central nervous system (CNS) that is important in motor control and in certain aspects of behavior. The presence of endogenous or exogenous dopamine in the periphery also affects cardiovascular function.

71
Q

Inotropic

A

Refers to a substance that increases muscular contraction force (positive inotrope) or decreases contraction force (negative inotrope). Certain cardiac drugs are considered positive inotropes because they increase the force of cardiac contractions.

72
Q

Pharmacotherapeutics

A

The study of how drugs are used in the prevention and treatment of disease.

73
Q

Phosphodiesterase (PDE)

A

An enzyme that breaks down phosphodiester bonds in organic compounds. Certain phosphodiesterases are important clinically because they break down second messengers such as cyclic AMP, and drugs that inhibit these enzymes prolong the effects of cyclic AMP in the lungs and other tissues.

74
Q

Anticoagulation

A

A decrease in the blood’s capacity to coagulate (clot). Drugs with the ability to decrease coagulation are known as anticoagulants.

75
Q

Fibrinolytics

A

Drugs which facilitate the breakdown and dissolution of clots that have already formed. These drugs work by converting plasminogen (profibrinolysin) to plasmin (fibrinolysin).

76
Q

Hemophilia

A

A hereditary disease in which an individual is unable to synthesize adequate amounts of a specific clotting factor.

77
Q

Hemostasis

A

The process of preventing blood loss from the circulation following injury to blood vessels (ANT: hemorrhage).

78
Q

Thrombus

A

A blood clot formed by the activation of fibrin and platelets. Excessive thrombus formation (thrombosis) can be controlled by drugs that affect various aspects of the clotting mechanisms.

79
Q

Hyperlipidemia

A

A chronic and excessive increase in plasma lipids in the blood.